ACM
Aisling Capital Management Portfolio holdings
AUM
$476M
1-Year Est. Return
128.63%
This Fund
S&P 500
1 Year Est. Return
+128.63%
AUM
$476M
AUM Growth
-$2.63M
(-0.55%)
Holding
14
Top Buys
| 1 | +$4.87M | |
| 2 | +$2.62M | |
| 3 | +$1.59M | |
| 4 |
CMPS
Compass Pathways
CMPS
|
+$1.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$12.5B
| $378M | 79.35% |
5,089,611
|
|
||
2
Syndax Pharmaceuticals
SNDX
$1.63B
| $30.8M | 6.46% |
1,316,806
|
|
||
3
Monte Rosa Therapeutics
GLUE
$1.5B
| $25.6M | 5.37% |
1,555,664
+83,333
|
|
||
|
BCAX
4
Bicara Therapeutics
BCAX
$1.29B
| $11.3M | 2.38% |
568,919
|
|
||
|
BBOT
5
BridgeBio Oncology
BBOT
$659M
| $9.11M | 1.91% |
1,018,018
+453,393
|
|
||
|
CMPS
6
Compass Pathways
CMPS
$1.8B
| $7.92M | 1.66% |
1,432,336
+233,918
|
|
||
7
Scholar Rock
SRRK
$5.34B
| $3.79M | 0.8% |
77,031
|
|
||
8
Biomea Fusion
BMEA
$99.1M
| $3.13M | 0.66% |
2,048,757
|
|
||
|
EPRX
9
Eupraxia Pharmaceuticals
EPRX
$436M
| $2.35M | 0.49% |
+325,000
|
|
||
10
UroGen Pharma
URGN
$1.29B
| $1.94M | 0.41% |
108,000
|
|
||
11
Aclaris Therapeutics
ACRS
$648M
| $1.63M | 0.34% |
434,455
|
|
||
12
Marker Therapeutics
MRKR
$24M
| $423K | 0.09% |
325,370
|
|
||
|
OKUR
13
OnKure Therapeutics
OKUR
$170M
| $367K | 0.08% |
88,607
|
|
||
14
CalciMedica
CALC
$12.6M
| – | – |
-521,114
|
|